Real-world study of camrelizumab combined with apatinib mesylate in treatment of solid tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200059488

Enrollment

Unknown

Registered

2022-05-02

Start date

2022-04-25

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age: >= 18 years old, male or female; 2. ECOG score 0-2 points; 3. Patients with solid tumors confirmed by pathology or histology; 4. At least one measurable lesion (according to RECIST v 1.1 standard); 5. For patients who fail first-line or second-line treatment or whose solid tumors cannot tolerate standard treatment; 6. Expected survival period >= 3 months; 7. Patients who have previously used immunosuppressants and or anti-angiogenic drugs are not excluded; 8. For female patients who have not undergone menopause or surgical sterilization: agree to abstinence or use effective contraceptive methods during the treatment period and at least 7 months after the last dose of the study treatment; 9. The researchers believe that they can benefit; 10. Volunteer to join this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Except for patients with contraindications to carrilizumab and/or Apatinib mesylate, i.e. contraindicated for those allergic to carrilizumab and its excipients; apatinib mesylate should be prohibited in persons allergic to any component; it should be prohibited in patients with active bleeding, ulcers, intestinal perforation, intestinal obstruction, drug-uncontrolled hypertension within 30 days after major surgery, Grade III-IV cardiac insufficiency (NYHA standard), and severe hepatic and renal insufficiency (Grade 4). 3. Doctors think that they are not suitable for inclusion; the researchers judge that the tumor is very likely to invade important blood vessels during the follow-up study and cause fatal massive bleeding.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
Objective remission rate;Disease control rate;Overall survival;Quality of life score;	—

Countries

China

Contacts

Public ContactLi Ning

Henan Cancer Hospital

happy201901@126.com+86 13526501903

Outcome results